Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Divalproex Sodium Extended-Release (ER) Tablets USP,250 mg and 500 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Depakote®Extended-Release Tablets, 250 mg and 500 mg, of AbbVie Inc.

Lupin’s Divalproex Sodium ER Tablets USP, 250 mg and 500 mgare indicated for:

• Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features
• Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures
• Prophylaxis of migraine headaches

Divalproex Sodium Extended-Release (ER) Tablets USP, 250 mg and 500 mg(RLD: Depakote® ER)had annualsales ofapproximatelyUSD159million in the U.S. (IQVIA MATJune2019).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8^thlargest generics pharmaceutical company by revenues (31^stMar 2019, Bloomberg LTM) respectively. The Company is the 3^rdlargest pharmaceutical player in the US by prescriptions (IQVIA MAT Jun 2019); 3^rdlargest Indian pharmaceutical company by global revenues (31^stMar 2019, Bloomberg LTM); 5^thlargest generic pharmaceutical player in Japan and 6^thlargest company in the Indian Pharmaceutical Market (IQVIA MAT Jun 2019).

For the financial year ended 31^stMarch 2019, Lupin’s Consolidated sales and Net profits were at Rs. 163,694 million (USD 2.34 billion) and Rs. 9,466 million (USD 136 million) respectively. Please visit https://www.lupin.com  for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal/

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Arvind Bothra
Head – Investor Relations and M&A/ Corporate Communications
Email: arvindbothra@lupin.com
Ph: +91-22-66408237

*Safe Harbor Statement

Depakote® is a registered trademark of Sanofi.